SIGLEC1 and hepatocellular carcinoma: Studies have shown that low‐dose IFN‐α causes macrophage polarization into the CD169+ phenotype, enhancing their phagocytic capacity and increasing CD8+ T cell activation, thereby inhibiting human hepatocellular carcinoma (HCC) [39].